Wolfe Research Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to “Peer Perform”

Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by equities researchers at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat.com reports.

Several other brokerages also recently commented on ALNY. Chardan Capital increased their target price on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a report on Friday, August 1st. Wells Fargo & Company upped their price objective on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Raymond James Financial assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 target price on the stock. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Finally, Bank of America increased their price target on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a “buy” rating in a research report on Friday, July 11th. Four analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.04.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $418.91 on Monday. The stock has a market capitalization of $54.91 billion, a PE ratio of -169.60 and a beta of 0.25. The company’s 50-day moving average is $323.41 and its 200-day moving average is $281.19. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.98. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $426.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The business had revenue of $773,689 billion during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. Alnylam Pharmaceuticals’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.13) EPS. Equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the company’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer directly owned 48,948 shares of the company’s stock, valued at approximately $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth approximately $27,000. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $28,000. Whipplewood Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 69 shares in the last quarter. Finally, Colonial Trust Co SC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.